
The PacificRx library
Clear answers. Informed next steps.
Explore tirzepatide, semaglutide, GLP-1 care, and peptide evidence through practical, source-linked patient guides.
Start with a topic
GIP / GLP-1 education
Explore topic SemaglutideGLP-1 education
Explore topic GLP-1Metabolic care education
Explore topic BPC-157Research and evidence
Explore topic NAD+Cellular biology and evidence
Explore topic TesamorelinProduct-specific evidence
Explore topic PeptidesEvidence before treatment
Explore topicWhere a therapy is in the regulatory journey
Tags describe the named therapy and use at the review date, not the age or design of a cited paper. Development can stop or change; phase 3 results do not imply an application is submitted or under FDA review. Designations support development and are separate from approval. Approval applies to a specific product and indication, not to compounded preparations. General care articles may cover multiple stages and have no single therapy tag.
Patient guides
Page 2 of 3
Guide 2 min
FDA-Approved, Investigational, and Compounded Peptides: What the Terms Mean
FDA-approved, investigational, and compounded describe different regulatory contexts. An approved medicine has a specific product and indication; investigational treatment is still being studied; a compounded preparation is not FDA-approved before marketing.
Read guideGuide 2 min
How to Verify an Online Pharmacy Before Ordering Prescription Medication
Use the state board of pharmacy's official license database to verify the dispensing pharmacy, then confirm its U.S. contact details, prescription requirement, and access to a licensed pharmacist.
Read guideGuide 2 min
BPC-157: FDA Approval vs. a Registered Clinical Trial
A registered BPC-157 study is a research record, not FDA marketing approval or proof that a treatment works. Read the study's status, design, population, outcomes, and published results separately from the regulatory status of any product being offered.
Read guideGuide 2 min
BPC-157 for Tendon Injuries: Questions the Evidence Must Answer
A BPC-157 recovery claim needs human evidence relevant to the actual tendon injury, formulation, and outcome. Animal findings alone cannot establish improved healing, return to activity, or safety in people.
Read guideGuide 2 min
BPC-157 Research-Only Labels and COAs: What They Do Not Establish
A research-use-only label and a certificate of analysis do not establish that BPC-157 is an approved, effective, or safe patient treatment. Laboratory testing, clinical evidence, legitimate dispensing, and an individualized treatment decision are separate questions.
Read guideGuide 2 min
NAD+, NR, and NMN: Different Substances, Different Evidence
NAD+ is a coenzyme involved in cellular metabolism. NR and NMN are related precursors, not alternative names for the same product.
Read guideGuide 2 min
NAD+ IV Evidence: Reading Longevity and Energy Claims Carefully
The importance of NAD+ in cells does not prove that an NAD+ infusion improves longevity or treats fatigue. Evaluate route-specific human studies, meaningful outcomes, comparison groups, and harms before interpreting a cellular-energy claim as a demonstrated patient benefit.
Read guideGuide 2 min
NAD+ Injections and Infusions: Sterile-Compounding Questions
The FDA has warned that food-grade NAD+ is unsuitable for sterile compounding without appropriate processing because microbial and endotoxin contamination can harm patients. Ask about the actual preparation, pharmacy, quality controls, and adverse-event response before interpreting a purity claim as an assurance of injectable quality.
Read guideGuide 2 min
Tesamorelin and EGRIFTA: Approved Use vs. General Weight Loss
EGRIFTA WR contains tesamorelin and is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states that it is not indicated for weight-loss management.
Read guideGuide 2 min
Tesamorelin Monitoring: Questions About IGF-1 and Glucose
Tesamorelin product labeling addresses increased IGF-1 and the risk of glucose intolerance or diabetes. Before treatment, ask the clinician how relevant history, baseline findings, follow-up, and symptoms will inform an individualized plan.
Read guideGuide 2 min
EGRIFTA WR, EGRIFTA SV, and Compounded Tesamorelin: Formulation Matters
EGRIFTA WR and EGRIFTA SV have different product-specific doses, preparation steps, and storage instructions; the WR label states that they are not substitutable. A compounded tesamorelin preparation is another distinct product question.
Read guide
Cancer researchRYZ101 · GEP-NETs; investigational, not FDA approved · Status checked 2026-10-14
Guide 4 min
Can a Peptide Target Cancer? RYZ101 and the ACTION-1 Study
A peptide guides an investigational radioactive therapy to tumor receptors. What the phase 3 ACTION-1 announcement shows—and what remains unanswered.
Read guide
GLP-1Guide 4 min
Online GLP-1 Consultation: What to Prepare and Ask
Prepare for an online weight-management consultation with a practical checklist of records, questions, costs, and follow-up expectations.
Read guide
Patient careGuide 4 min
How to Evaluate an Online Peptide Therapy Provider
Questions to ask about clinician credentials, evidence, pharmacy fulfillment, pricing, and follow-up before requesting peptide care online.
Read guide
GLP-1Wegovy · labeled weight-management use; compounded products are not FDA approved · Status checked 2026-10-14
Guide 5 min
What Is Semaglutide?
A practical guide to how semaglutide works, why clinician screening matters, and what patients should understand before starting.
Read guide
GLP-1Zepbound · labeled weight-management use; compounded products are not FDA approved · Status checked 2026-10-14
Guide 5 min
What Is Tirzepatide?
How dual GIP/GLP-1 signaling differs from older metabolic medications and why dose selection should be individualized.
Read guide
Weight ManagementGuide 6 min
Semaglutide vs Tirzepatide
A patient-friendly comparison of two major metabolic therapy pathways and the factors that shape physician selection.
Read guide
LongevityGuide 4 min
What Is NAD+?
NAD+ is central to cellular energetics, but human evidence is mainly biochemical and early physiologic rather than proof of longevity or disease-prevention benefit.
Read guide